Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer

Tanya B. Dorff, Cathy M. Tangen, E. David Crawford, Daniel P. Petrylak, Celestia S. Higano, Derek Raghavan, David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Maha H A Hussain

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

Original languageEnglish (US)
Pages (from-to)69-77
Number of pages9
JournalTherapeutic Advances in Medical Oncology
Volume1
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Prostatic Neoplasms
docetaxel
Androgens
Drug Therapy
Castration
Prednisone
Biomarkers
Quality of Life
Clinical Trials
Technology
Survival
Therapeutics

Keywords

  • Advanced prostate cancer
  • Androgen deprivation
  • Chemotherapy
  • Clinical trials

ASJC Scopus subject areas

  • Oncology

Cite this

Dorff, T. B., Tangen, C. M., Crawford, E. D., Petrylak, D. P., Higano, C. S., Raghavan, D., ... Hussain, M. H. A. (2009). Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer. Therapeutic Advances in Medical Oncology, 1(2), 69-77. https://doi.org/10.1177/1758834009343454

Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer. / Dorff, Tanya B.; Tangen, Cathy M.; Crawford, E. David; Petrylak, Daniel P.; Higano, Celestia S.; Raghavan, Derek; Quinn, David I.; Vogelzang, Nicholas J.; Thompson, Ian M.; Hussain, Maha H A.

In: Therapeutic Advances in Medical Oncology, Vol. 1, No. 2, 2009, p. 69-77.

Research output: Contribution to journalArticle

Dorff, TB, Tangen, CM, Crawford, ED, Petrylak, DP, Higano, CS, Raghavan, D, Quinn, DI, Vogelzang, NJ, Thompson, IM & Hussain, MHA 2009, 'Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer', Therapeutic Advances in Medical Oncology, vol. 1, no. 2, pp. 69-77. https://doi.org/10.1177/1758834009343454
Dorff, Tanya B. ; Tangen, Cathy M. ; Crawford, E. David ; Petrylak, Daniel P. ; Higano, Celestia S. ; Raghavan, Derek ; Quinn, David I. ; Vogelzang, Nicholas J. ; Thompson, Ian M. ; Hussain, Maha H A. / Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer. In: Therapeutic Advances in Medical Oncology. 2009 ; Vol. 1, No. 2. pp. 69-77.
@article{3ae3dd99c5fe4cdda84bb053bf025ac7,
title = "Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer",
abstract = "The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-na{\"i}ve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.",
keywords = "Advanced prostate cancer, Androgen deprivation, Chemotherapy, Clinical trials",
author = "Dorff, {Tanya B.} and Tangen, {Cathy M.} and Crawford, {E. David} and Petrylak, {Daniel P.} and Higano, {Celestia S.} and Derek Raghavan and Quinn, {David I.} and Vogelzang, {Nicholas J.} and Thompson, {Ian M.} and Hussain, {Maha H A}",
year = "2009",
doi = "10.1177/1758834009343454",
language = "English (US)",
volume = "1",
pages = "69--77",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Cooperative group trials - Southwest oncology group (SWOG) innovations in advanced prostate cancer

AU - Dorff, Tanya B.

AU - Tangen, Cathy M.

AU - Crawford, E. David

AU - Petrylak, Daniel P.

AU - Higano, Celestia S.

AU - Raghavan, Derek

AU - Quinn, David I.

AU - Vogelzang, Nicholas J.

AU - Thompson, Ian M.

AU - Hussain, Maha H A

PY - 2009

Y1 - 2009

N2 - The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

AB - The major goals of the Southwest oncology genitourinary (SWOG-GU) committee in the area of advanced prostate cancer are to improve the survival and quality of life (QOL) of patients with advanced prostate cancer. SWOG trials have examined the role of combined androgen blockade, intermittent androgen deprivation, and the early application of chemotherapy in castration-naïve disease. In addition, they have contributed to advancing the current chemotherapy standard of docetaxel plus prednisone, and ongoing trials seek to improve upon that standard. Finally, surrogate endpoints have been identified and markers of treatment response or resistance with novel technology are under active investigation. This review highlights findings from recent SWOG clinical trials for advanced prostate cancer, emphasizing the clinical impact and future applications of the data.

KW - Advanced prostate cancer

KW - Androgen deprivation

KW - Chemotherapy

KW - Clinical trials

UR - http://www.scopus.com/inward/record.url?scp=77953443633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953443633&partnerID=8YFLogxK

U2 - 10.1177/1758834009343454

DO - 10.1177/1758834009343454

M3 - Article

VL - 1

SP - 69

EP - 77

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 2

ER -